Peddock Capital Advisors LLC owns $4.85 million in Thermo Fisher Scientific Inc. (NYSE:TMO)

Vaseline2 days ago

0 5 minutes read

Peddock Capital Advisors LLC increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 0.5% during the third quarter, HoldingsChannel.com reports. The firm owned 7,834 shares of the medical research company’s stock after purchasing an additional 38 shares during the period. Thermo Fisher Scientific makes up 1.2% of Peddock Capital Advisors LLC’s portfolio, making the stock its 17th biggest position. Peddock Capital Advisors LLC’s holdings in Thermo Fisher Scientific were worth $4,846,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Beaumont Financial Advisors LLC boosted its stake in Thermo Fisher Scientific by 0.8% in the first quarter. Beaumont Financial Advisors LLC now owns 2,199 shares of the medical research company’s stock valued at $1,278,000 after acquiring an additional 17 shares during the period. Cedar Wealth Management LLC boosted its stake in Thermo Fisher Scientific by 14.5% in the first quarter. Cedar Wealth Management LLC now owns 134 shares of the medical research company’s stock valued at $78,000 after acquiring an additional 17 shares during the period. Lafayette Investments Inc. boosted its stake in Thermo Fisher Scientific by 2.1% in the second quarter. Lafayette Investments Inc. now owns 830 shares of the medical research company’s stock valued at $459,000 after acquiring an additional 17 shares during the period. Patrick M Sweeney & Associates Inc. boosted its stake in Thermo Fisher Scientific by 1.8% in the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,031 shares of the medical research company’s stock valued at $570,000 after acquiring an additional 18 shares during the period. Finally, Drive Wealth Management LLC raised its stake in Thermo Fisher Scientific by 0.9% in the second quarter. Drive Wealth Management LLC now owns 2,123 shares of the medical research company’s stock valued at $1,175,000 after acquiring an additional 18 shares during the period. Institutional investors own 89.23% of the company’s shares.

Thermo Fisher Scientific stock rose 0.0%

Shares of NYSE TMO traded up $0.01 during trading on Wednesday, reaching $595.46. The company had a trading volume of 183,519 shares, compared to its average volume of 1,464,380. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $627.88. The stock has a market cap of $227.47 billion, a PE ratio of 38.17, a P/E/G ratio of 3.83 and a beta of 0.77. The company’s 50-day moving average is $608.95, and its 200-day moving average is $582.99. The company has a quick ratio of 1.37, a current ratio of 1.72, and a debt-to-equity ratio of 0.64.

Want more great investment ideas?

Thermo Fisher Scientific (NYSE:TMO – Get Your Free Report ) last issued its earnings results on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The company had revenue of $10.54 billion for the quarter, compared to analysts’ expectations of $10.50 billion. During the same period last year, the firm posted earnings of $5.15 per share. The company’s quarterly revenue was down 1.4% year-over-year. As a group, equities analysts estimate that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current fiscal year.

Thermo Fisher Scientific announces dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be paid a dividend of $0.39 per share. This represents an annualized dividend of $1.56 and a dividend yield of 0.26%. The ex-dividend date of this dividend is Friday, September 13. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Analysts on Wall Street are forecasting an increase

A number of research firms have weighed in on TMO. Evercore ISI raised their target price on Thermo Fisher Scientific from $605.00 to $630.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. UBS Group raised Thermo Fisher Scientific to a “strong-buy” rating in a report on Monday, September 16th. Wells Fargo & Company started coverage on Thermo Fisher Scientific in a report on Tuesday, August 27th. They set an “overweight” rating and a $670.00 price objective for the company. Stephens began coverage on Thermo Fisher Scientific in a report on Tuesday, October 1st. They set an “overweight” rating and a $680.00 price objective for the company. Finally, JPMorgan Chase & Co. upped their target price on Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an “overweight” rating in a research note on Friday, September 20th. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Moderate Buy” and an average target price of $653.72, based on data from MarketBeat.com.

View the latest stock report on TMO

Indoor activity

In other news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $600.85, for a total transaction of $180,255.00. Following the sale, the executive vice president now directly owns 17,887 shares in the company, valued at $10,747,403.95. This trade represents a 0.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 860 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 26th. The shares were sold at an average price of $611.03, for a total value of $525,485.80. Following the sale, the chief accounting officer now directly owns 1,814 shares in the company, valued at approximately $1,108,408.42. The trade was a 0.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible via this link. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 26th. The shares were sold at an average price of $600.85, for a total transaction of $180,255.00. Following the completion of the sale, the executive vice president now owns 17,887 shares in the company, valued at approximately $10,747,403.95. This represents a 0.00 % decrease in ownership of the shares. The disclosure for this sale can be found here. Insiders have sold 23,084 shares of company stock worth $14,094,292 over the last three months. Company insiders own 0.34% of the company’s shares.

About Thermo Fisher Scientific

(Free report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics and laboratory products and biopharmaceutical services in North America, Europe, Asia-Pacific and internationally. The company’s Life Sciences Solutions segment provides reagents, instruments and supplies for biological and medical research, drug and vaccine discovery and production, and infection and disease diagnosis; and solutions include biosciences, genetic sciences and biological manufacturing for the pharmaceutical, biotech, agricultural, clinical, healthcare, academic and government markets.